Background. Governments and health care regulators now require hospitals and nursing homes to establish programs to monitor and report antimicrobial consumption and resistance. However, additional resources were not provided. We sought to develop an approach for monitoring antimicrobial resistance and consumption that health care systems can implement with minimal added costs or modifications to existing diagnostic and informatics infrastructure.
Antimicrobial resistance (AMR) poses one of the greatest threats to global public health [1, 2] . To help address the ongoing crisis of escalating AMR, governments and health care regulators recently required hospitals and nursing homes to establish programs to monitor and report antimicrobial consumption and resistance, but they did not provide additional funds or resources to facilitate compliance [3, 4] . Lack of funding is a major barrier to compliance, and participation in such stewardship programs is also linked to reimbursement by the Centers for MedicareMedicaid Services (CMS) and a new Joint Commission (JC) standard [3] [4] [5] [6] . The ability of large and geographically dispersed health care systems to trend antibiotic use and resistance with a minimum of additional resources would facilitate regulatory compliance and inform preventive strategies. Although many conventional and novel strategies are being employed to fight the escalating problem of antimicrobial resistance, reports using configurations and combinations of existing medical informatics, software, and diagnostic platforms are scarce.
We aimed to develop an approach for monitoring antibiotic resistance and antibiotic consumption that health systems can implement with minimal cost or modification to existing electronic health care information and bacterial diagnostic systems. Our method used resources already existing at or freely available to most health care systems: (1) an electronic health record and/or laboratory information system linked to an automated diagnostic platform (ie, Seimens MicroScan, BD Phoenix, or bioMérieux Vitek II), (2) open source software, (3) a microbiologist, and (4) an epidemiologist or statistician.
To demonstrate the utility of the approach, we then sought to see if it could be applied to a large, geographically dispersed national health care network (the Department of Defense [DoD] ) to analyze trends in antibiotic prescriptions and resistance. We chose Staphylococcus aureus as the prototype because it is a leading cause of serious health care-associated infections in the United States, and it is the most common cause of soft tissue infections and infective endocarditis worldwide [7] [8] [9] [10] . Furthermore, we studied the incidence of a specific subtype of S. aureus we termed "problematic vancomycin-susceptible S. aureus" (PVSSA) and the usage of major antistaphylococcal agents in the DoD. We chose the term PVSSA for the following rationale.
First, it would be one of the most challenging and problematic antibiotic-microbe ("drug-bug") combinations for such an approach. Although manual broth dilution is the reference standard for determining vancomycin minimum inhibitory concentration (MIC), it is laborious and infeasible in busy hospital laboratories, especially for testing thousands of isolates. Therefore, hospitals unavoidably rely on commercial automated antibiotic susceptibility testing (AST) platforms. The 3 most popular platforms are the Phoenix, Vitek, and MicroScan, and larger health systems may use more than 1 platform. In fact, the DoD has 288 fixed location treatment facilities and uses all 3 platforms. Furthermore, the reported MIC for S. aureus can vary according to the type of AST platform used, especially in the upper ranges of susceptible-intermediate [11] . Therefore this "drug-bug" combination would be one of the least amenable to and most "problematic" for automated electronic data mining and reporting across large health networks that use more than 1 type of AST platform and process large volumes of isolates. Second, a vancomycin MIC between 1.5 and 2.0 µg/mL, although in the sensitive range, had previously been associated with adverse outcomes and mortality in S. aureus bacteremia. Therapeutic failure had occurred even for methicillin-susceptible S. aureus (MSSA) strains [12] [13] [14] [15] .
Our main goal was to illustrate an alternative approach, using freely available software, for analyzing and reporting of large volumes of drug consumption and antibiotic resistance data support of stewardship efforts. A byproduct of having successfully met that goal would be the ability to use it to investigate correlations between usage of a drug (in this case, antistaphylococcal agents) and increases in mean MICs of a key therapeutic (in this example, vancomycin) among S. aureus.
Only 2 basic types of data are needed for SAVANT analyses: (1) the number of isolates per month meeting a prespecified drug susceptibility, either a categorical variable (S, I, or R) or a numeric value of minimum inhibitory concentrations; and (2) some unit of drug consumption per month, either milligrams, grams, prescriptions, day of therapy, or defined daily doses. Examples of the required data format and code are provided in the Supplementary Appendix (sample_input_data).
METHODS

Vancomycin-Susceptible S. aureus Isolates and Susceptibility Data
The DoD's health system, its beneficiaries, and detailed methods for mining its electronic health records (EHRs) have been described previously [16, 17] . Briefly, there are 280 fixed location treatment facilities. Most are ambulatory clinics and medium-sized community hospitals (150-bed average). Eleven of those are larger tertiary referral centers located in the states of California, Hawaii, Maryland, North Carolina, Ohio, Texas, Virginia, Washington, and Germany. All hospitals are accredited by the Joint Commission. Health care beneficiaries include all races and ages including neonates and elderly residents of longterm skilled nursing facilities (not just young active duty soldiers and sailors). The EHRs of all beneficiaries (approximately 9.2 million annually) were queried for all cultures that grew vancomycin-susceptible S. aureus (VSSA). All isolates are from infections or suspected infections because polymerase chain reaction-based platforms are used for surveillance screening of nares for colonization. As such, no surveillance isolates are produced and available for further analysis. Data were deduplicated based on 1 isolate per patient per month using a "30-day interval from initial isolate" scheme [18] . Monthly counts of both community-acquired and hospital-acquired VSSA isolates, defined as those with vancomycin MICs of ≤2 µg/mL, were tabulated from January 2010 through December 2015. MICs were determined by automated methods with the bioMérieux Vitek II, Siemens MicroScan Walkaway, or BD Phoenix testing platforms, depending on the hospital, and were interpreted according to Clinical and Laboratory Standards Institute guidelines. Due to the known diminished reliability of automated vancomycin MIC measurements >2 µg/mL and because our focus was on susceptible isolates, we only considered isolates with MICs no greater than 2 µg/mL. Similarly, we did not include those having uninterpretable values (eg, a reported MIC of "≤2 µg/mL" rather than 0.25, 1.0, etc.) in our definition of PVSSA. S. aureus (SA) isolates were also stratified on the basis of methicillin susceptibility.
We determined both proportion-and rate-based measures of PVSSA incidence [18, 19] . The proportion was defined as the number of PVSSA (1.5 µg/mL < MIC ≤ 2 µg/mL) samples per 100 VSSA (MIC ≤ 2 µg/mL) isolates, and the rate was defined as the number of PVSSA isolates per 1000 patient encounters.
Antistaphylococcal Drug Use
Inpatient and outpatient prescription rates (ie, prescriptions per 1000 encounters) from January 2010-December 2015 were calculated for 8 key antistaphylococcal compounds: vancomycin, daptomycin, linezolid, doxycycline, trimethoprim-sulfamethoxazole, cefazolin, cephalexin, and nafcillin. We evaluated associations with various prescription rates both within the current time period (ie, rate of prescription in the same month as the rate of PVSSA) and lagged 1 month (ie, rate of prescription in the previous month compared with the rate of PVSSA in the current month).
Trends in Staphylococcal Resistance and Antistaphylococcal Use
Our goal was to develop a method for semi-automated trending and predicting incidences of PVSSA across large health care networks using an EHR network. To demonstrate the usefulness of this approach, we sought to (1) determine trends in PVSSA incidence rates and proportions over a 6-year observation period, (2) test whether PVSSA incidence differed geospatially or by facility type (referral or community hospital), and (3) determine consumption trends for relevant therapeutics. To ensure that this approach wasn't limited to a single drug-bug combination, we performed the same analyses with a different antistaphylococcal drug. We examined whether the proportions of MRSA and MSSA isolates that were also PVSSA were significantly different using the chi-square test. Comparisons of VSSA and PVSSA incidences were performed using the 2-sample proportion test.
In addition, we used 2 methods to analyze and report trends in antistaphylococcal use and resistance, time series analysis and the autoregressive integrated moving average (ARIMA). We then used generalized linear regression to see if results from all methods were concordant, and to see if any associations existed between drug use and resistance. Time series analysis can reveal trends in historical observations of a variable of interest and forecast that variable's behavior in the future [20] [21] [22] [23] . Seasonal trend decomposition using Loess (STL) is a mathematical procedure to divide time series data into 3 components: seasonal variation, a trend, and random noise. ARIMA uses an autoregressive moving average to trend values of a variable of interest based on its past observed values. PVSSA incidence levels were predicted with the seasonal ARIMA models using the adjusted Akaike information criterion as an objective function. The optimal model was then fitted to in-sample data and used to generate forecasts about the data series' behavior 24 months into the future (January 2016 through December 2017).
Trends in prescription rates were extracted using STL decomposition, and their significance was assessed using basic MannKendall tests. Pearson's correlation coefficient was calculated to assess the robustness of results under differing comparative measures.
Composite time series were disaggregated into seasonal, trend, and residual components using a local regression-based, Loess decomposition technique (STL) [24] . Seasonal and basic Mann-Kendall tests assessed the significance of trends in aggregate series and extracted trend components, respectively [25] .
All time series-related analyses were performed using the R forecast package [26] . Other statistics were performed on R, version 3, and SAS, version 9 [27] .
Generalized linear models were calculated using the PROC GLM statement in SAS. Each variable was assessed at the univariate level. Model building was accomplished in reverse stepwise fashion to arrive at the most parsimonious model. PVSSA rate and PVSSA percentage as outcome variables were modeled separately.
RESULTS
Quality Control of Input Data, and Regional and Service-Specific Variation of PVSSA Incidences
Six and a half million bacterial cultures were obtained from 230 million patient encounters during the 2010-2015 study period, yielding 81 840 unique (1 isolate per patient per month) VSSA isolates. The testing platform could not be confirmed for 8.0% of VSSA isolates, so these data were excluded from further analysis (Figure 1 ). Antibiotic susceptibilities of the remaining VSSA isolates were assayed on 3 platforms; 58.2% of these were tested on Vitek, 19.8% on MicroScan, and 14.0% on Phoenix. Initial trend analysis using combined data collected on all 3 platforms suggested that the incidence of VSSA was increasing at a biologically implausible rate, inconsistent with trends reported in other US populations or in previous reports of the DoD population [16, [28] [29] [30] . Therefore, for the final analysis, we excluded results collected on MicroScan from further analysis because this platform reports erroneously high vancomycin MICs, upwardly skewing the apparent number of PVSSA isolates [11] . This platform-driven erroneous effect and trend are illustrated in Supplementary Figure 1 and explained in more detail in the "Discussion" section.
Reliable vancomycin susceptibility data from the Phoenix or Vitek instruments were therefore available for 58 558 unique clinical isolates. VSSA rates and PVSSA proportions significantly differed between geographic regions and military branch. The highest rates of VSSA were at Navy and Army facilities in the eastern United States, and the highest proportions of PVSSA occurred at naval facilities in the northwest and southeast.
Overall, VSSA and PVSSA incidences were significantly higher in the South, and proportions of VSSA were significantly lower in the North. See incidence_by_region.xlsx in the Supplementary Data files. The rates and proportions of PVSSA were significantly different between Navy/Army and Navy/Air Force, but not between Army/Air Force (See incidence_by_ser-vice.xlsx in the Supplementary Data files).
Trends in PVSSA Incidences and Antistaphylococcal Use
The incidence rates of VSSA and PVSSA decreased over the study period (Figure 2, top and middle panels) . Furthermore, the proportion of VSSA isolates that were PVSSA also decreased from 2010 to 2015 (Figure 2, bottom panel) .
These downward trends were observed throughout the DoD and did not vary by military branch or facility type (community or referral) (data not shown). Rate-based PVSSA incidence had a strong seasonal component, peaking in roughly late summer, the nadir being during the late fall/early winter (data not shown). Seasonal variation was much less pronounced for proportion-based PVSSA incidence. All usage trends of the 8 antistaphylococcal antibiotics were downward or flat (Figure 3 ).
It was difficult to infer contributory relationships between antibiotic use and PVSSA incident proportions as the trends in both fluctuated in the same directions. Therefore, we compared their relative rates of change, that is, the number of prescriptions per month, with the monthly incident proportion of PVSSA (Figure 4) . The red lines indicate the overall trend. A positive slope indicates that the denominator (PVSSA incidence) was decreasing faster than the numerator (number of prescriptions) was decreasing.
SAVANT and Other Combinations
We performed the same analyses with a different antistaphylococcal drug as an extra control or validation. We chose trimethoprim sulfamethoxazole because it is one of the most frequently prescribed agents, it is primarily used for Staphylococcal infections, (unlike doxycycline, which is heavily used for malaria prophylaxis in this population), and because there are prior studies of resistance trends that we could use as frames of reference [31, 32] . Trends of incidence rates and proportions of trimethoprim-sulfamethoxazole-resistant S. aureus over the same period are not shown.
Linear Regression
As a second type of validation, we then compared how STL-and ARIMA-based results compared with those obtained by a more commonly used analysis, linear regression. Generalized linear regression analyses revealed trends in PVSSA incidence and antistaphylococcal compound usage that agreed with trends determined by the STL and ARIMA methods (Table 1) .
Using either rate or proportion of PVSSA as the outcome variable, we found that both were also decreasing over time ( orange bolding) . Results of lagged prescription rates were similar to the current prescription rates (data available from the corresponding author).
DISCUSSION
As the JC and government agencies mandate new ASP standards and conditions of participation for reimbursement in acute and long-term care facilities [3, 4, 33] , semi-or fully automated analysis of antibiotic use-resistance relationships would facilitate regulatory and reporting compliance. Here, we demonstrate an approach that clinical laboratories and integrated health care networks can use to monitor such relationships with minimal additional investment in their existing electronic health record or laboratory information system infrastructure. Furthermore, SAVANT can monitor trends for antimicrobial-pathogen combinations other than vancomycin and S. aureus. Three elements are required: the free program R, an electronic health record system, and an epidemiologist or biostatistician. In this case, both the pathogen of interest (PVSAA) and the usage of antistaphylococcal antibiotics decreased over the observation period, but PVSSA decreased significantly faster than antibiotic use. Five of the 8 antistaphylococcal drugs studied associated (either positively or negatively) with PVSSA proportions or rates. We also examined whether there might be a delay between antibiotic exposure and observed changes in PVSSA frequency by stratifying the results via a 1-month and 6-month time-lagged approach. This did not change the overall results, nor did stratification by methicillin susceptibility.
Use-resistance relationships have been reported previously, and our results in this study were congruent with those studies [17, 32] . Similar to previous reports, we found that incidences and trends of S. aureus varied by season and geographic region [28, 30, 34] . Infection prevention and surveillance are not fully standardized or uniformly applied across all 3 services. Certain locations may have more intense activity due to research studies or performance improvement initiatives [35] [36] [37] . This could account for the differences between the 3 military branches. However, other investigators do not believe that differential application of infection prevention strategies accounted for the regional differences they observed [30] . They posit that bio-ecologic or molecular/clonal differences might be a major reason [30] . Military training populations are at risk for skin and soft tissue infections caused by S. aureus, especially those in close living conditions [35] [36] [37] . In this observation, regions that had Army bases with the largest numbers of basic trainees and/or Naval bases that supported submarines (northwest and southeast) had higher incidences of S. aureus. Based on time series analysis and generalized linear regression, the Air Force had the lowest incidences of S. aureus while the Army and Navy had higher amounts. In the Air Force, living conditions are generally more advanced (access to showers) during deployments, and basic training is less physical or trauma-prone, resulting in fewer wounds and less skin irritation. As most of the isolates in this study were from wounds or skin and soft tissue infections, the timing was similar to other studies with peaks in the hotter, more humid months [34] . The seasonal variation we observed was more pronounced in incidence rates than incidence proportions, so perhaps there were more patients with skin diseases or injuries during those times.
Our results are notable for several reasons. First, they were derived from one of the largest microbiological data sets and a large, geographically dispersed managed care network in the United States. Epidemiologists can apply a "plug and play" approach by analogizing the branches of the military to their local/regional integrated health or hospital networks (ie, replace Army with Ascension, Navy with Kaiser Permanente, and Air Force with Hospital Corporation of America); all DoD hospitals are required to maintain JC accreditation standards and are increasingly mandated to participate in national reporting and stewardship requirements such as the National Health Safety Network.
Second, clinical practitioners are generally more concerned with proportions as a means to guide empirical therapy, while epidemiologists and/or public policy makers are often more interested in the burden of resistance in a population at a given point in time, which is arguably better captured using rates [19] . Therefore, to accommodate the interests of both groups, we used 2 measures of PVSSA incidence: (1) the proportion of PVSSA relative to 100 vancomycin-susceptible S. aureus isolates tested and (2) the rate of PVSSA isolates per inpatient per 1000 days.
Third, the MicroScan has been implicated in potentially overcalling true vancomycin MICs of 1 µg/mL for S. aureus [11] , and our findings were consistent with this (Supplementary Figure 1) . The true incidence of PVSSA in our study was less than 2%, but when we initially included the MicroScan data, we obtained an erroneous incidence of almost 50%. Reportedly, newer panels that have been released since these data were acquired and MicroScan-derived data for vancomycin-Staphylococcus should be able to be included in future approaches. Furthermore, that MicroScan limitation would not apply to other drug-bug combinations such as carbapenem-Enterobacteriaceae.
An important limitation of this study is the that fact that we used the number of prescriptions for outpatients and the number of physician orders for inpatients as proxies for actual amounts of antibiotics consumed instead of days of therapy or defined daily dose. This was unavoidable in the case of outpatient use. The number and dispersion of facilities in the health care system made it nearly impossible to get precise patient-days or patientyears of inpatient antibiotic usage for the entire system. However, to make querying the full DoD electronic health records system for such drug usage data feasible, this potential tradeoff in accuracy was required. Furthermore, unlike the DoD, an increasing number of hospitals and managed care systems do have ready access to days of therapy and defined daily doses, which would permit more robust assessment of use-resistance relationships. However, our goal was not to provide a standardized defined daily dose metric for comparison with other networks or countries. Nor did we seek to definitively determine whether usage of antistaphylococcal agents correlated with increases in mean minimum inhibitory concentrations of a key therapeutic (vancomycin) among S. aureus. To be clear, although the cost to implement SAVANT is negligible, some expertise is required, but most larger hospitals and nearly all multicenter health networks already have that expertise in the form of a microbiologist and an epidemiologist or data analyst. Another limitation of SAVANT is that most commercially available electronic health care systems do not provide ready access to advanced types of antibiotic usage data such as defined daily doses or days of therapy. Therefore, some level of algorithm development or purchase of the software package is required. However, basic tallies of number of prescriptions and numbers of targeted isolates meeting a certain predetermined characteristic can be readily queried by the pharmacy and microbiology laboratory. Additionally, many of the major vendors have on-site support staff for developing electronic best practice alerts and automated user-defined queries. For example, our regional health system in Rochester, New York, like many others, uses EPIC CareConnect, which provides "physician and clinical builders. " They are a vendor-certified team whose responsibility is to participate in the design, development, and implementation of tools to perform the clinical activities of the electronic medical record. They have participated in automating monthly "days of antibiotic therapy" reports for the stewardship program.
Despite these limitations, this study shows how SAVANT is a low-cost, useful approach for enhancing antimicrobial stewardship efforts. Hospital and health care networks can utilize this technique on electronic medical information systems regardless of the microbiology identification and susceptibility testing platform or bacteria-antibiotic combination.
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